TrialNature medicine2024

Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Rebecca A Shatsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.